The document discusses the future of the generic pharmaceutical industry. It notes that while generics currently provide low-cost access to older drugs, significantly improving health will require more innovation. The document advocates for generic companies to invest more in R&D compared to manufacturing. It also suggests seeking disruptive technologies that could transform companies and the industry. The future may involve new models focused on areas like biologics, services, data, and personalized medicine rather than just generics.
Orthopaedic Device Industry Business Models: 2020 and BeyondApril Bright
During last year’s closing keynote, Dr. Wael Barsoum underscored the importance of producing transformational, innovative products to stay competitive and maintain a strong company and a healthy supply chain. This year, Dr. Bill Tribe will shine the “innovation lens” on the value of transforming your business.
Dr. Tribe co-authored the often-cited “Medical Devices: Equipped for the Future?” study in which the orthopaedics sector is called out specifically as facing an extreme combination of forces — none of which come as a surprise or are new, but when viewed holistically (as in the image below), paint a rather obvious picture of the need for companies to respond. As you can see, orthopaedics is the only sector with 4 of 5 “hot” areas…and in this case, the odd one out (regulatory scrutiny) is still marked “critical.”
From a top-down view, the five “disruptors” listed above are acute (power shift to payors, regulatory scrutiny, unclear sources of innovation, new healthcare delivery models, need to serve lower socio-economic classes). They impact the overall orthopaedic industry intensely – but how are they impacting you? Dr. Tribe’s Keynote Address will take into account the uniqueness of the OMTEC audience: large and small OEMs, Suppliers and Service Providers.
As stated in the A.T. Kearney study, “Each company faces a different set of headwinds…while the macro-factors held true, individual experiences and prioritization depended on factors such as market geography, product life cycles and go-to-market strategies. The most effective strategies are therefore likely to be company specific.”
What will be your business model in 2020? 2025?
Will you be considering cost-structure, deployment of inventory, commercial logistics, quality and regulatory frameworks, R&D, innovation and data collection?
Dr. Tribe will break down the issues and share potential approaches to help you navigate toward a more relevant and lucrative business model – regardless of where you are in the process.
Orthopaedic Care Shifts to Outpatient and Urgent Care ClinicsApril Bright
The Shift in Care Delivery - As the healthcare delivery system evolves, hospitals may no longer be the first stop for patients seeking orthopaedic care. This is evidenced by the growing trend of surgeons moving to the outpatient setting, as patients seek less invasive procedures. Orthopaedic urgent care centers have also emerged as a viable alternative, due to their ability to address price concerns in the industry by reducing time and overhead costs for both providers and patients.
Attendees gain more insight into this shift, and learn how it will affect demands on manufacturers from a product design and delivery standpoint.
Accelerated Medical Diagnostics is developing PlatinDx, a diagnostic test that predicts sensitivity to platinum-based chemotherapy drugs. The company was founded in 2008 and is led by CEO Paul Henderson along with CTO George Cimino and CSO William Hope. PlatinDx works by microdosing patients with chemotherapeutics and using accelerator mass spectrometry to analyze DNA samples to determine resistance or sensitivity. The total addressable market is $5 billion for solid cancers treated with chemotherapy worldwide, with the served available market of $1 billion in the US and a target market of $250 million for bladder cancer in the US. AMD conducted customer interviews and market testing through the UCSF LLP program to refine their value proposition and focus
AI Innovation in the Pharmaceutical Sector - Accelerating ResearchDaniel Faggella
This is a deck I presented at the OECD's International Symposium on Machine Learning and Artificial Intelligence in Mexico City, October 2019.
The presentation draws from a number of AI executive interviews and in-depth research on AI innovation in pharma R&D, much of which is available on Emerj: https://emerj.com/?s=pharma
Optimization and management observations and ideas for clinical studiesrpochadt
This document outlines challenges facing clinical trials and proposes ideas to improve efficiency. It notes that clinical trials are increasingly time-consuming, expensive, and complex. Several ideas are presented to help address these issues, including making trials more adaptive, leveraging technology like cloud computing and mobile devices, improving data management systems, and learning from practices in other industries like Six Sigma. The document advocates bringing more of these types of ideas to clinical trials in order to help accelerate the process and better support researchers and patients.
PharmaLedger Press Release #2 June 2020 PharmaLedger
The PharmaLedger project is a 36-month collaboration between pharmaceutical companies and other entities to develop a blockchain platform and use cases for supply chain, clinical trials, and health data. Selected use cases focus on investigational drug supply chains, matching patients to trials, digitizing clinical trial consent, and integrating medical device data. The project aims to accelerate healthcare innovation through improved trust, transparency, and data sharing across stakeholders while protecting patient privacy.
This document describes a patented, cloud-based system called MD Backline that automates patient contact before and after office visits through email or SMS. The system aims to improve patient care by asking how treatment is going, providing customized education, answering questions, collecting outcomes data, and generating research revenue. MD Backline has been tested with over 5,000 responses showing high response rates and positive feedback. It has delivered value to practices by reducing calls and documenting education. After two years of funding operations through $900k in revenue, projections estimate $4.9M in year 1 revenue growing to over $70M in year 3. The next steps are to expand to more specialties, EHR platforms, and seek investment partners.
The document discusses the future of the generic pharmaceutical industry. It notes that while generics currently provide low-cost access to older drugs, significantly improving health will require more innovation. The document advocates for generic companies to invest more in R&D compared to manufacturing. It also suggests seeking disruptive technologies that could transform companies and the industry. The future may involve new models focused on areas like biologics, services, data, and personalized medicine rather than just generics.
Orthopaedic Device Industry Business Models: 2020 and BeyondApril Bright
During last year’s closing keynote, Dr. Wael Barsoum underscored the importance of producing transformational, innovative products to stay competitive and maintain a strong company and a healthy supply chain. This year, Dr. Bill Tribe will shine the “innovation lens” on the value of transforming your business.
Dr. Tribe co-authored the often-cited “Medical Devices: Equipped for the Future?” study in which the orthopaedics sector is called out specifically as facing an extreme combination of forces — none of which come as a surprise or are new, but when viewed holistically (as in the image below), paint a rather obvious picture of the need for companies to respond. As you can see, orthopaedics is the only sector with 4 of 5 “hot” areas…and in this case, the odd one out (regulatory scrutiny) is still marked “critical.”
From a top-down view, the five “disruptors” listed above are acute (power shift to payors, regulatory scrutiny, unclear sources of innovation, new healthcare delivery models, need to serve lower socio-economic classes). They impact the overall orthopaedic industry intensely – but how are they impacting you? Dr. Tribe’s Keynote Address will take into account the uniqueness of the OMTEC audience: large and small OEMs, Suppliers and Service Providers.
As stated in the A.T. Kearney study, “Each company faces a different set of headwinds…while the macro-factors held true, individual experiences and prioritization depended on factors such as market geography, product life cycles and go-to-market strategies. The most effective strategies are therefore likely to be company specific.”
What will be your business model in 2020? 2025?
Will you be considering cost-structure, deployment of inventory, commercial logistics, quality and regulatory frameworks, R&D, innovation and data collection?
Dr. Tribe will break down the issues and share potential approaches to help you navigate toward a more relevant and lucrative business model – regardless of where you are in the process.
Orthopaedic Care Shifts to Outpatient and Urgent Care ClinicsApril Bright
The Shift in Care Delivery - As the healthcare delivery system evolves, hospitals may no longer be the first stop for patients seeking orthopaedic care. This is evidenced by the growing trend of surgeons moving to the outpatient setting, as patients seek less invasive procedures. Orthopaedic urgent care centers have also emerged as a viable alternative, due to their ability to address price concerns in the industry by reducing time and overhead costs for both providers and patients.
Attendees gain more insight into this shift, and learn how it will affect demands on manufacturers from a product design and delivery standpoint.
Accelerated Medical Diagnostics is developing PlatinDx, a diagnostic test that predicts sensitivity to platinum-based chemotherapy drugs. The company was founded in 2008 and is led by CEO Paul Henderson along with CTO George Cimino and CSO William Hope. PlatinDx works by microdosing patients with chemotherapeutics and using accelerator mass spectrometry to analyze DNA samples to determine resistance or sensitivity. The total addressable market is $5 billion for solid cancers treated with chemotherapy worldwide, with the served available market of $1 billion in the US and a target market of $250 million for bladder cancer in the US. AMD conducted customer interviews and market testing through the UCSF LLP program to refine their value proposition and focus
AI Innovation in the Pharmaceutical Sector - Accelerating ResearchDaniel Faggella
This is a deck I presented at the OECD's International Symposium on Machine Learning and Artificial Intelligence in Mexico City, October 2019.
The presentation draws from a number of AI executive interviews and in-depth research on AI innovation in pharma R&D, much of which is available on Emerj: https://emerj.com/?s=pharma
Optimization and management observations and ideas for clinical studiesrpochadt
This document outlines challenges facing clinical trials and proposes ideas to improve efficiency. It notes that clinical trials are increasingly time-consuming, expensive, and complex. Several ideas are presented to help address these issues, including making trials more adaptive, leveraging technology like cloud computing and mobile devices, improving data management systems, and learning from practices in other industries like Six Sigma. The document advocates bringing more of these types of ideas to clinical trials in order to help accelerate the process and better support researchers and patients.
PharmaLedger Press Release #2 June 2020 PharmaLedger
The PharmaLedger project is a 36-month collaboration between pharmaceutical companies and other entities to develop a blockchain platform and use cases for supply chain, clinical trials, and health data. Selected use cases focus on investigational drug supply chains, matching patients to trials, digitizing clinical trial consent, and integrating medical device data. The project aims to accelerate healthcare innovation through improved trust, transparency, and data sharing across stakeholders while protecting patient privacy.
This document describes a patented, cloud-based system called MD Backline that automates patient contact before and after office visits through email or SMS. The system aims to improve patient care by asking how treatment is going, providing customized education, answering questions, collecting outcomes data, and generating research revenue. MD Backline has been tested with over 5,000 responses showing high response rates and positive feedback. It has delivered value to practices by reducing calls and documenting education. After two years of funding operations through $900k in revenue, projections estimate $4.9M in year 1 revenue growing to over $70M in year 3. The next steps are to expand to more specialties, EHR platforms, and seek investment partners.
Wallace H. Coulter c3i - Addressable Market PresentationHeidjer Staecker
This document provides guidance on how to properly assess the market potential for a new technology. It emphasizes that the focus should be on solving customer needs rather than just the product itself. Key steps include understanding who the target customers are, what problems they currently face and how they address those problems now, who the major competitors are, and determining if the new technology clearly provides benefits over existing solutions. The document also stresses understanding market trends, size, regulatory hurdles, intellectual property landscape, and identifying the appropriate business model to successfully commercialize the technology. Product-market fit is an important first step, but more work is needed to navigate risks, determine the path to market, and establish a sustainable business.
This document outlines a workshop on differentiation strategies for generic drug companies. The workshop covers current differentiation approaches, challenges to differentiation, ideas for potential strategies, and future trends. Session 1 introduces the topic and reviews examples like PiSA Farmaceutica's integrated healthcare approach. Session 2 discusses challenges around resources, expertise, and changing organizations. Session 3 generates ideas around product leadership, operational excellence, and customer intimacy. Session 4 speculates on future industry shifts like prevention-focused care and personalized medicine.
Michael Alvers, Transinsight, DE (Fortissimo)I4MS_eu
The document discusses using high-performance computing (HPC) for drug-target binding simulations. It describes how HPC resources from the Fortissimo project enable performing over 450 million pairwise molecule-ligand comparisons, allowing for novel drug target prediction, side effect prediction, and drug repositioning. Two universities implemented and optimized distributed algorithms to run the drug binding simulations on HPC infrastructure 5-10 times faster. This provides a framework for previously impossible bioinformatics analyses to discover new drugs.
This document provides an overview of marketing strategies for early-stage biotech startups. It discusses how early-stage marketing can assess market potential and address investor concerns. Key aspects of a marketing portfolio are outlined, including market research, branding, pitch decks, and gaining exposure. Early-stage marketing goals are highlighted as well as metrics that are important to investors like market opportunity, proven traction, team strengths, and unique value proposition. Resources for market research and positioning are also provided.
How to Create a Big Data Culture in PharmaChris Waller
A talk presented at the Big Data and Analytics conference in Boston on January 28, 2014. Emphasis on data and information sharing cultures in companies.
This document summarizes findings from a field trip to Silicon Valley regarding options for Finnish healthtech startups to enter the US market. It outlines trends in health technology, interesting new startups, and the innovation ecosystem in Silicon Valley. It then discusses US gateway options such as accelerators, partners, and venture capital firms investing in health. Finally, it provides recommendations on understanding the market stage and category to determine the best entry approach.
Playing to win in the life science tools marketBill Kelly
For the last year, clients have repeatedly been asking us similar questions:
- What's the outlook for life science funding?
- What's the impact of large mergers on the competitive environment?
- Are the ways scientists purchase products changing?
- Do new technologies represent a threat or an opportunity?
BioInformatics LLC has decided to answer these questions in our latest multi-sponsor research report, Competitive Strategies in an Era of Consolidation & Disruptive Technologies. We will undertake a comprehensive assessment of the current state of the global life science through extensive interviews with market participants, industry observers, procurement specialists and a survey of more than a thousand scientific customers from all market segments.
The Changing Pharma R&D Model, GDDIS Leaders Summit Ted Torphy CSO, Head, External Innovation Research Excellence, Advance Technologies Janssen R&D
A Johnson & Johnson Pharmaceutical Company
Previous Position
www.gbx.uk.com
www.gddis.com
www.gddif.com
www.wddis.com
The presentation discusses the use of wearable devices and sensors for collecting data in clinical trials. While consumer wearables are becoming more common, their data may not be suitable for labeling claims with regulatory agencies without proper validation and approval. Major pharmaceutical companies are exploring how mobile health technologies can supplement traditional trial data collection methods to make trials less costly and more convenient. However, simply having FDA approval as a medical device does not guarantee its data can be used to support drug approval. Proper infrastructure, analytics, and clinical expertise is needed to incorporate sensor data into clinical trials in a way that is robust, secure, and produces scientific results.
Artificial Intelligence Service in HealthcareAnkit Jain
It is no secret that artificial intelligence is shaping new business landscapes in every industries. As one of emerging convergence technologies, Artificial Intelligence (AI) creates new products and services, finally innovating business models. Especially, it has been noted by industry experts and researchers that healthcare sector has the biggest potential of AI convergence. In fact, major technology companies including Google, Microsoft and IBM have invested in AI in healthcare sector. Thousands of AI startups are active launching innovative services related to healthcare.
Big data analytics is being used in healthcare and disease management to gain knowledge and insights from large datasets. Hypothesis validation and creation can lead to knowledge when applying big data techniques. Causal relationships between variables can be identified from data to understand the causes of events and alter outcomes. However, correlation does not always indicate causation, and confounding factors must be considered. Genomics data in particular poses challenges due to its large volume, velocity, variety and other attributes, but can be applied from research to precision medicine through genetic testing.
Actionable Intelligence: Finding Insights & OpportunitiesHubbard One
The document discusses how the digital universe is exploding with more data being created every day. Professionals are overwhelmed by the increasing amount of information from more sources. It argues we need better, not just more, information. It provides examples of how competitive and financial intelligence can provide insights into opportunities for client development, market prioritization, and constructing pitches. The examples analyze potential opportunities with BP, UAR/CO, and Medtronic to determine which may be the most profitable. Medtronic is identified as the best opportunity due to the firm's experience and connections as well as Medtronic's litigation spend.
ColVenture aims to provide medical history and healthcare information solutions in Colombia through various products like cards, jewelry, and bracelets. Their mission is to give patients and primary care access to medical histories during emergencies or when changing doctors. The team sees an opportunity in Colombia's unexplored health information market and plans to develop customizable prototypes. They are building a demo website and bracelet prototype. The business model involves marketing to medical directors and gaining regulatory approval. Partnerships with the government and device providers will be important, as will funding from angel investors or loans.
The Southern California Consortium for Technology and Innovation in Pediatrics (CTIP) is one of seven FDA-funded pediatric device consortia working to develop medical devices for children. CTIP engages clinicians, engineers, entrepreneurs and others in developing pediatric technologies through events like Med-Innovation Rounds and symposiums. They provide support to 35 distinct pediatric device projects in their first year. To convince industry partners of opportunities in pediatrics, CTIP clearly defines projects' value propositions and market potential through due diligence. Their strategy pairs entrepreneurs with domain experts to advance technologies for children.
This document discusses prediction markets as an alternative to traditional market research surveys. Prediction markets engage participants to trade virtual currency based on their predictions about new products and concepts. A case study showed that prediction market participants provided more accurate assessments of new products than traditional surveys. The document argues that while prediction markets have been shown to be more effective, many companies are still reluctant to replace traditional normative databases with this approach due to risks associated with product launch failures.
“The Most Recommended Pharma & Life Sciences Solution providers in 2021” highlighting the pharmaceutical and healthcare industries help to improving the human health and forwarding life-expectancy one step further.
Professor Yoon Sup Choi discusses digital health and the future of healthcare centered around changes in the pharmaceutical industry. He notes that three key steps in implementing digital medicine are: 1) measuring data through devices like smartphones, wearables, and genetic analysis; 2) collecting the data; and 3) gaining insights from the data using artificial intelligence. Choi also provides an overview of the digital health industry landscape and increasing investment in digital health startups from pharmaceutical companies and other investors.
1. Bio-Modeling Systems is a French company that uses its proprietary CADITM Discovery platform to generate mechanistic models of diseases and their underlying biological mechanisms.
2. The company was founded in 2004 and has since led collaborations resulting in two therapeutic spin-offs in clinical trials and publications in peer-reviewed journals.
3. CADITM Discovery integrates human and artificial intelligence to address the complexity of biological mechanisms and unreliability of scientific publications in a novel discovery paradigm.
Artificial intelligence in field of pharmacyKaustav Dey
AI is a program designed to produce outcome in a manner similar to human intelligence,logic and reasoning.This can be used in field of Pharmacy for betterment of humankind, to save lives,money and time
This document summarizes Dr. Scott Farrell's presentation on the role universities can play in developing medical technologies. It discusses Dalhousie University's involvement in developing Uresta, a new type of pessary to treat urinary incontinence. The presentation outlines the challenges of translating ideas to products, including funding, regulations, intellectual property, and manufacturing. It describes Dalhousie's support through clinical trials, patenting, business advice, and helping find partners for production and distribution of Uresta.
Defending Weapons Offence Charges: Role of Mississauga Criminal Defence LawyersHarpreetSaini48
Discover how Mississauga criminal defence lawyers defend clients facing weapon offence charges with expert legal guidance and courtroom representation.
To know more visit: https://www.saini-law.com/
Lifting the Corporate Veil. Power Point Presentationseri bangash
"Lifting the Corporate Veil" is a legal concept that refers to the judicial act of disregarding the separate legal personality of a corporation or limited liability company (LLC). Normally, a corporation is considered a legal entity separate from its shareholders or members, meaning that the personal assets of shareholders or members are protected from the liabilities of the corporation. However, there are certain situations where courts may decide to "pierce" or "lift" the corporate veil, holding shareholders or members personally liable for the debts or actions of the corporation.
Here are some common scenarios in which courts might lift the corporate veil:
Fraud or Illegality: If shareholders or members use the corporate structure to perpetrate fraud, evade legal obligations, or engage in illegal activities, courts may disregard the corporate entity and hold those individuals personally liable.
Undercapitalization: If a corporation is formed with insufficient capital to conduct its intended business and meet its foreseeable liabilities, and this lack of capitalization results in harm to creditors or other parties, courts may lift the corporate veil to hold shareholders or members liable.
Failure to Observe Corporate Formalities: Corporations and LLCs are required to observe certain formalities, such as holding regular meetings, maintaining separate financial records, and avoiding commingling of personal and corporate assets. If these formalities are not observed and the corporate structure is used as a mere façade, courts may disregard the corporate entity.
Alter Ego: If there is such a unity of interest and ownership between the corporation and its shareholders or members that the separate personalities of the corporation and the individuals no longer exist, courts may treat the corporation as the alter ego of its owners and hold them personally liable.
Group Enterprises: In some cases, where multiple corporations are closely related or form part of a single economic unit, courts may pierce the corporate veil to achieve equity, particularly if one corporation's actions harm creditors or other stakeholders and the corporate structure is being used to shield culpable parties from liability.
Wallace H. Coulter c3i - Addressable Market PresentationHeidjer Staecker
This document provides guidance on how to properly assess the market potential for a new technology. It emphasizes that the focus should be on solving customer needs rather than just the product itself. Key steps include understanding who the target customers are, what problems they currently face and how they address those problems now, who the major competitors are, and determining if the new technology clearly provides benefits over existing solutions. The document also stresses understanding market trends, size, regulatory hurdles, intellectual property landscape, and identifying the appropriate business model to successfully commercialize the technology. Product-market fit is an important first step, but more work is needed to navigate risks, determine the path to market, and establish a sustainable business.
This document outlines a workshop on differentiation strategies for generic drug companies. The workshop covers current differentiation approaches, challenges to differentiation, ideas for potential strategies, and future trends. Session 1 introduces the topic and reviews examples like PiSA Farmaceutica's integrated healthcare approach. Session 2 discusses challenges around resources, expertise, and changing organizations. Session 3 generates ideas around product leadership, operational excellence, and customer intimacy. Session 4 speculates on future industry shifts like prevention-focused care and personalized medicine.
Michael Alvers, Transinsight, DE (Fortissimo)I4MS_eu
The document discusses using high-performance computing (HPC) for drug-target binding simulations. It describes how HPC resources from the Fortissimo project enable performing over 450 million pairwise molecule-ligand comparisons, allowing for novel drug target prediction, side effect prediction, and drug repositioning. Two universities implemented and optimized distributed algorithms to run the drug binding simulations on HPC infrastructure 5-10 times faster. This provides a framework for previously impossible bioinformatics analyses to discover new drugs.
This document provides an overview of marketing strategies for early-stage biotech startups. It discusses how early-stage marketing can assess market potential and address investor concerns. Key aspects of a marketing portfolio are outlined, including market research, branding, pitch decks, and gaining exposure. Early-stage marketing goals are highlighted as well as metrics that are important to investors like market opportunity, proven traction, team strengths, and unique value proposition. Resources for market research and positioning are also provided.
How to Create a Big Data Culture in PharmaChris Waller
A talk presented at the Big Data and Analytics conference in Boston on January 28, 2014. Emphasis on data and information sharing cultures in companies.
This document summarizes findings from a field trip to Silicon Valley regarding options for Finnish healthtech startups to enter the US market. It outlines trends in health technology, interesting new startups, and the innovation ecosystem in Silicon Valley. It then discusses US gateway options such as accelerators, partners, and venture capital firms investing in health. Finally, it provides recommendations on understanding the market stage and category to determine the best entry approach.
Playing to win in the life science tools marketBill Kelly
For the last year, clients have repeatedly been asking us similar questions:
- What's the outlook for life science funding?
- What's the impact of large mergers on the competitive environment?
- Are the ways scientists purchase products changing?
- Do new technologies represent a threat or an opportunity?
BioInformatics LLC has decided to answer these questions in our latest multi-sponsor research report, Competitive Strategies in an Era of Consolidation & Disruptive Technologies. We will undertake a comprehensive assessment of the current state of the global life science through extensive interviews with market participants, industry observers, procurement specialists and a survey of more than a thousand scientific customers from all market segments.
The Changing Pharma R&D Model, GDDIS Leaders Summit Ted Torphy CSO, Head, External Innovation Research Excellence, Advance Technologies Janssen R&D
A Johnson & Johnson Pharmaceutical Company
Previous Position
www.gbx.uk.com
www.gddis.com
www.gddif.com
www.wddis.com
The presentation discusses the use of wearable devices and sensors for collecting data in clinical trials. While consumer wearables are becoming more common, their data may not be suitable for labeling claims with regulatory agencies without proper validation and approval. Major pharmaceutical companies are exploring how mobile health technologies can supplement traditional trial data collection methods to make trials less costly and more convenient. However, simply having FDA approval as a medical device does not guarantee its data can be used to support drug approval. Proper infrastructure, analytics, and clinical expertise is needed to incorporate sensor data into clinical trials in a way that is robust, secure, and produces scientific results.
Artificial Intelligence Service in HealthcareAnkit Jain
It is no secret that artificial intelligence is shaping new business landscapes in every industries. As one of emerging convergence technologies, Artificial Intelligence (AI) creates new products and services, finally innovating business models. Especially, it has been noted by industry experts and researchers that healthcare sector has the biggest potential of AI convergence. In fact, major technology companies including Google, Microsoft and IBM have invested in AI in healthcare sector. Thousands of AI startups are active launching innovative services related to healthcare.
Big data analytics is being used in healthcare and disease management to gain knowledge and insights from large datasets. Hypothesis validation and creation can lead to knowledge when applying big data techniques. Causal relationships between variables can be identified from data to understand the causes of events and alter outcomes. However, correlation does not always indicate causation, and confounding factors must be considered. Genomics data in particular poses challenges due to its large volume, velocity, variety and other attributes, but can be applied from research to precision medicine through genetic testing.
Actionable Intelligence: Finding Insights & OpportunitiesHubbard One
The document discusses how the digital universe is exploding with more data being created every day. Professionals are overwhelmed by the increasing amount of information from more sources. It argues we need better, not just more, information. It provides examples of how competitive and financial intelligence can provide insights into opportunities for client development, market prioritization, and constructing pitches. The examples analyze potential opportunities with BP, UAR/CO, and Medtronic to determine which may be the most profitable. Medtronic is identified as the best opportunity due to the firm's experience and connections as well as Medtronic's litigation spend.
ColVenture aims to provide medical history and healthcare information solutions in Colombia through various products like cards, jewelry, and bracelets. Their mission is to give patients and primary care access to medical histories during emergencies or when changing doctors. The team sees an opportunity in Colombia's unexplored health information market and plans to develop customizable prototypes. They are building a demo website and bracelet prototype. The business model involves marketing to medical directors and gaining regulatory approval. Partnerships with the government and device providers will be important, as will funding from angel investors or loans.
The Southern California Consortium for Technology and Innovation in Pediatrics (CTIP) is one of seven FDA-funded pediatric device consortia working to develop medical devices for children. CTIP engages clinicians, engineers, entrepreneurs and others in developing pediatric technologies through events like Med-Innovation Rounds and symposiums. They provide support to 35 distinct pediatric device projects in their first year. To convince industry partners of opportunities in pediatrics, CTIP clearly defines projects' value propositions and market potential through due diligence. Their strategy pairs entrepreneurs with domain experts to advance technologies for children.
This document discusses prediction markets as an alternative to traditional market research surveys. Prediction markets engage participants to trade virtual currency based on their predictions about new products and concepts. A case study showed that prediction market participants provided more accurate assessments of new products than traditional surveys. The document argues that while prediction markets have been shown to be more effective, many companies are still reluctant to replace traditional normative databases with this approach due to risks associated with product launch failures.
“The Most Recommended Pharma & Life Sciences Solution providers in 2021” highlighting the pharmaceutical and healthcare industries help to improving the human health and forwarding life-expectancy one step further.
Professor Yoon Sup Choi discusses digital health and the future of healthcare centered around changes in the pharmaceutical industry. He notes that three key steps in implementing digital medicine are: 1) measuring data through devices like smartphones, wearables, and genetic analysis; 2) collecting the data; and 3) gaining insights from the data using artificial intelligence. Choi also provides an overview of the digital health industry landscape and increasing investment in digital health startups from pharmaceutical companies and other investors.
1. Bio-Modeling Systems is a French company that uses its proprietary CADITM Discovery platform to generate mechanistic models of diseases and their underlying biological mechanisms.
2. The company was founded in 2004 and has since led collaborations resulting in two therapeutic spin-offs in clinical trials and publications in peer-reviewed journals.
3. CADITM Discovery integrates human and artificial intelligence to address the complexity of biological mechanisms and unreliability of scientific publications in a novel discovery paradigm.
Artificial intelligence in field of pharmacyKaustav Dey
AI is a program designed to produce outcome in a manner similar to human intelligence,logic and reasoning.This can be used in field of Pharmacy for betterment of humankind, to save lives,money and time
This document summarizes Dr. Scott Farrell's presentation on the role universities can play in developing medical technologies. It discusses Dalhousie University's involvement in developing Uresta, a new type of pessary to treat urinary incontinence. The presentation outlines the challenges of translating ideas to products, including funding, regulations, intellectual property, and manufacturing. It describes Dalhousie's support through clinical trials, patenting, business advice, and helping find partners for production and distribution of Uresta.
Similar to Life Science Bootcamp IP Slides v1.0 (20)
Defending Weapons Offence Charges: Role of Mississauga Criminal Defence LawyersHarpreetSaini48
Discover how Mississauga criminal defence lawyers defend clients facing weapon offence charges with expert legal guidance and courtroom representation.
To know more visit: https://www.saini-law.com/
Lifting the Corporate Veil. Power Point Presentationseri bangash
"Lifting the Corporate Veil" is a legal concept that refers to the judicial act of disregarding the separate legal personality of a corporation or limited liability company (LLC). Normally, a corporation is considered a legal entity separate from its shareholders or members, meaning that the personal assets of shareholders or members are protected from the liabilities of the corporation. However, there are certain situations where courts may decide to "pierce" or "lift" the corporate veil, holding shareholders or members personally liable for the debts or actions of the corporation.
Here are some common scenarios in which courts might lift the corporate veil:
Fraud or Illegality: If shareholders or members use the corporate structure to perpetrate fraud, evade legal obligations, or engage in illegal activities, courts may disregard the corporate entity and hold those individuals personally liable.
Undercapitalization: If a corporation is formed with insufficient capital to conduct its intended business and meet its foreseeable liabilities, and this lack of capitalization results in harm to creditors or other parties, courts may lift the corporate veil to hold shareholders or members liable.
Failure to Observe Corporate Formalities: Corporations and LLCs are required to observe certain formalities, such as holding regular meetings, maintaining separate financial records, and avoiding commingling of personal and corporate assets. If these formalities are not observed and the corporate structure is used as a mere façade, courts may disregard the corporate entity.
Alter Ego: If there is such a unity of interest and ownership between the corporation and its shareholders or members that the separate personalities of the corporation and the individuals no longer exist, courts may treat the corporation as the alter ego of its owners and hold them personally liable.
Group Enterprises: In some cases, where multiple corporations are closely related or form part of a single economic unit, courts may pierce the corporate veil to achieve equity, particularly if one corporation's actions harm creditors or other stakeholders and the corporate structure is being used to shield culpable parties from liability.
Genocide in International Criminal Law.pptxMasoudZamani13
Excited to share insights from my recent presentation on genocide! 💡 In light of ongoing debates, it's crucial to delve into the nuances of this grave crime.
सुप्रीम कोर्ट ने यह भी माना था कि मजिस्ट्रेट का यह कर्तव्य है कि वह सुनिश्चित करे कि अधिकारी पीएमएलए के तहत निर्धारित प्रक्रिया के साथ-साथ संवैधानिक सुरक्षा उपायों का भी उचित रूप से पालन करें।
This document briefly explains the June compliance calendar 2024 with income tax returns, PF, ESI, and important due dates, forms to be filled out, periods, and who should file them?.
Matthew Professional CV experienced Government LiaisonMattGardner52
As an experienced Government Liaison, I have demonstrated expertise in Corporate Governance. My skill set includes senior-level management in Contract Management, Legal Support, and Diplomatic Relations. I have also gained proficiency as a Corporate Liaison, utilizing my strong background in accounting, finance, and legal, with a Bachelor's degree (B.A.) from California State University. My Administrative Skills further strengthen my ability to contribute to the growth and success of any organization.
Guide on the use of Artificial Intelligence-based tools by lawyers and law fi...Massimo Talia
This guide aims to provide information on how lawyers will be able to use the opportunities provided by AI tools and how such tools could help the business processes of small firms. Its objective is to provide lawyers with some background to understand what they can and cannot realistically expect from these products. This guide aims to give a reference point for small law practices in the EU
against which they can evaluate those classes of AI applications that are probably the most relevant for them.
What are the common challenges faced by women lawyers working in the legal pr...lawyersonia
The legal profession, which has historically been male-dominated, has experienced a significant increase in the number of women entering the field over the past few decades. Despite this progress, women lawyers continue to encounter various challenges as they strive for top positions.
7. ®
Case Study: Advanced Proteome Therapeutics Corp. (Boston)
Size: 5-10 employees Sub-Sector: Biotechnology
Revenue: $1 M (US) Valuation: $13 M (US)
8. ®
Case Study: Advanced Proteome Therapeutics Corp. (Boston)
Schpiel: “We developed a proprietary protein modification platform
with the purpose of attaching entities to therapeutic proteins to
enhance their properties and/or endow them with additional
functions.”
Question: How much of the $13 M valuation do you think depends
upon TRADE SECRET protection measures? What measures?
9. ®
Case Study: Delivra Corp. (Ontario)
Size: 10 - 20 employees Sub-Sector: Health Care Technology
Revenue: $2.7 M (US) Valuation: $29 M (US)
10. ®
Case Study: Delivra Corp. (Ontario)
Schpiel: “We sell natural topical creams ... transdermal technologies
for the delivery of pharmaceutical and natural molecules, through
the skin, rather than via pills ... now seeking to license our unique,
proven, and patent-pending delivery platform to global
pharmaceutical companies for the transdermal delivery of third party
active ingredients to treat a broad range of conditions.”
Question: Should your friend buy stock in this company? What do
you want to know?
11. ®
Case Study: 3D Signatures Inc. (Manitoba)
Size: 20 – 50 employees Sub-Sector: Biotechnology
Revenue: $9.5 M (US) Valuation: $24 M (US)
12. ®
Case Study: 3D Signatures Inc. (Manitoba)
Schpiel: “We have a novel personalized medicine company with a
proprietary software platform based on the analysis of a patient's
three-dimensional chromosomal signature. The technology is well
developed and supported by 16 clinical studies …”
Question: Even though we were on a shoestring 3 years ago, I wish
we had ________________!! What can we do?
13. ®
Case Study: Emblem Corp. (Ontario)
Size: 20 - 50 employees Sub-Sector: Medical Marijuana
Revenue: $9.5 M (US) Valuation: $207 M (US)
14. ®
Case Study: Emblem Corp. (Ontario)
Schpiel: “We are a licensed producer of Medical Cannabis in Canada,
led by a team of former Healthcare & Pharma Executives who have
built & run multi-billion dollar companies. Our brand-new Ontario
facility was custom-designed and purpose-built specifically to
cultivate and cure cannabis for medicinal use.”
Question: Should your friend buy stock in this company? Is it a big
deal if they have to stop using “Emblem”?
15. ®
Case Study: Eyecarrot Innovations Corp. (Quebec)
Size: 5 - 10 employees Sub-Sector: Health Care Technology
Revenue: $1.9 M (US) Valuation: $14 M (US)
16. ®
Case Study: Eyecarrot Innovations Corp. (Quebec)
Schpiel: “a global, data-driven, expert therapeutic network to
transform how human Oculomotor Sensory performance is
diagnosed, exercised and enhanced. The company is building
BinoviTM, a universal, collaborative care platform that integrates
software, hardware, data and the expert knowledge of vision care
professionals to help patients on a global scale.”
Question: Should your friend buy stock in this company? Is it a big
deal if they have to stop using “Eyecarrot”?
17. ®
Case Study: VentriPoint Diagnostics Ltd. (Bellevue)
Size: 20 - 50 employees Sub-Sector: Health Care Technology
Revenue: $9.5 M (US) Valuation: $25 M (US)
18. ®
Case Study: VentriPoint Diagnostics Ltd. (Bellevue)
Schpiel: “a diagnostic ultrasound tool to monitor patients with heart
disease … the world’s first cost-effective and accurate diagnostic tool
for measuring right ventricle heart function. Canada and Europe have
granted approval for the sale of Ventripoint's VMS™ tool and the
company is pursuing the U.S. FDA marketing clearance through the
510(k) process.”
Question: Which type of IP does VentriPoint value most highly?